Retatrutide, from Soma, represents a exciting advance in metabolic management . This dual-action medication combines hormonal signaling properties with GIP pathway activation , indicating substantial results in patient studies for metabolic reduction . Researchers believe Retatrutide could provide a different option for patients experiencing weight